Prot #GA28950: Phase III, Double Blind, Placebo-Controlled, Multicenter Study Of The Efficacy And Safety Of Etrolizumab During Induction And Maintenance In Patients With Moderate To Severe Active Ulcerative Colitis Who Are Refractory To Or Intolerant Of T

Project: Research project

Project Details

StatusFinished
Effective start/end date4/20/15 → 4/20/21

Funding

  • Quintiles, Inc. (Prot #GA28950 // Prot #GA28950)
  • Genentech, Inc (Prot #GA28950 // Prot #GA28950)